title: Construction and immunogenicity of recombinant adenovirus vaccines expressing the HMW1, HMW2, or Hia adhesion protein of nontypeable Haemophilus influenzae.
abstract: The objective of the present study was to construct and assess the immunogenicity of recombinant adenovirus vectors expressing the HMW1, HMW2, or Hia protein of nontypeable Haemophilus influenzae (NTHi). These proteins are critical adhesins and potential protective antigens expressed by NTHi. Segments of the hmw1A and hmw2A structural genes that encode the distal one-half of mature HMW1 or HMW2 were cloned into the T7 expression vector pGEMEX-2. These constructs encoded stable HMW1 or HMW2 recombinant fusion protein that expresses B-cell epitopes common to most NTHi strains. A segment of the hia gene that encodes the surface-exposed portion of mature Hia was also cloned into pGEMEX-2. The resulting T7 gene 10 translational fusions were excised from the parent plasmids and cloned into the shuttle plasmid pDC316. Cotransfection of HEK 293 cells with the pDC316 derivatives and pBHGloxΔE1,3Cre resulted in the production of viral plaques from which recombinant adenoviruses expressing fusion proteins were recovered. Chinchillas immunized intraperitoneally with a single 10(8)-PFU dose of either the HMW2 or Hia adenoviral construct developed high anti-HMW2 or anti-Hia serum antibody titers within 4 weeks of immunization. Chinchillas immunized intranasally with a single 10(7)- to 10(9)-PFU dose of the Hia adenoviral construct also developed high anti-Hia serum antibody titers within 8 weeks of immunization. Recombinant adenoviruses represent a promising system to induce mucosal and systemic immunity and protection against mucosal diseases such as otitis media. Recombinant adenoviruses expressing recombinant HMW1, HMW2, or Hia protein will be important new tools in NTHi vaccine development efforts.
authors.affiliation: Department of Pediatrics, St. Louis University School of Medicine, 1100 South Grand Boulevard, Saint Louis, MO 63104, USA.
authors.forename: Linda E
authors.initials: LE
authors.lastname: Winter
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Barenkamp
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D018829:Adhesins, Bacterial / Q000235:genetics / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002460:Cell Line; D018985:Epitopes, B-Lymphocyte / Q000235:genetics / Q000276:immunology; D015870:Gene Expression; D005822:Genetic Vectors; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D006193:Haemophilus influenzae / Q000235:genetics / Q000276:immunology; D006801:Humans; D007274:Injections, Intraperitoneal; D010957:Plasmids; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D018985:Epitopes, B-Lymphocyte; C117431:HMW1 protein, bacteria; C117432:HMW2 protein, bacteria; D018073:Haemophilus Vaccines; C429644:Hia adhesin; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic